Literature DB >> 26307195

Alphavirus vectors as tools in neuroscience and gene therapy.

Kenneth Lundstrom1.   

Abstract

Alphavirus-based vectors have been engineered for in vitro and in vivo expression of heterelogous genes. The rapid and easy generation of replication-deficient recombinant particles and the broad range of host cell infection have made alphaviruses attractive vehicles for applications in neuroscience and gene therapy. Efficient delivery to primary neurons and hippocampal slices has allowed localization studies of gene expression and electrophysiological recordings of ion channels. Alphavirus vectors have also been applied for in vivo delivery to rodent brain. Due to the strong local transient expression provided by alphavirus vectors a number of immunization and gene therapy approaches have demonstrated both therapeutic and prophylactic efficacy in various animal models.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alphavirus vectors; Cancer gene therapy; Cancer vaccines; Micro-RNA; Neuroscience

Mesh:

Year:  2015        PMID: 26307195     DOI: 10.1016/j.virusres.2015.08.015

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  3 in total

1.  Visualization of the Oncolytic Alphavirus M1 Life Cycle in Cancer Cells.

Authors:  Jia Dan; Lin Nie; Xudong Jia; Cuiying Xu; Jing Cai; Yuan Lin; Jun Hu; Wenbo Zhu; Yinyin Li; Dong Chen; Ying Liu; Cheng Hu; Guangmei Yan; Jiankai Liang; Qinfen Zhang
Journal:  Virol Sin       Date:  2021-01-22       Impact factor: 4.327

2.  Rolling circle amplification: A high fidelity and efficient alternative to plasmid preparation for the rescue of infectious clones.

Authors:  Jeffrey M Marano; Christina Chuong; James Weger-Lucarelli
Journal:  Virology       Date:  2020-09-28       Impact factor: 3.616

Review 3.  Tumor angiogenesis and anti-angiogenic gene therapy for cancer.

Authors:  Tinglu Li; Guangbo Kang; Tingyue Wang; He Huang
Journal:  Oncol Lett       Date:  2018-05-17       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.